Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TAS-115 |
Synonyms | |
Therapy Description |
TAS-115 is a small molecule inhibitor of MET and KDR (VEGFR2), which may lead to angiogenesis blockade and tumor regression (PMID: 24140932). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAS-115 | MET Inhibitor 51 VEGFR2 Inhibitor 35 | TAS-115 is a small molecule inhibitor of MET and KDR (VEGFR2), which may lead to angiogenesis blockade and tumor regression (PMID: 24140932, PMID: 31820255). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KDR positive | pancreatic cancer | sensitive | TAS-115 | Preclinical | Actionable | In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932). | 24140932 |
Unknown unknown | Advanced Solid Tumor | not applicable | TAS-115 | Phase I | Actionable | In a Phase I trial, TAS-115 was well tolerated and deemed safe, and resulted in some preliminary efficacy in patients with advanced solid tumors (J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 2532). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|